Exploring a New Clinical Trial for KIT-Mutant GIST
Dr. Candace Haddox will discuss a new clinical trial combining ripretinib and navlimetostat for patients with KIT-mutant GIST and MTAP gene deletion, including eligibility and enrollment details.
Ponatinib Found to Have Therapeutic Potential for Drug-Resistant KIT mutations in GIST
A recent article in the Clinical Cancer Research Journal discussed a new drug, Ponatinib, that shows therapeutic potential for drug-resistant KIT mutations in GIST.